# 119-s-5043: Secure Drug Supply Chain Act of 2026

119-s-5043, Secure Drug Supply Chain Act of 2026, is a 119th Congress bill sponsored by Sen. Budd, Ted [R-NC] (R-NC); status introduced; PRIA reads it as touching household money (as of 2026-09-19).

- Canonical: https://policyrisk.com/legislation/119-s-5043
- As of: 2026-09-19
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-5043
- Congress: 119
- Title: Secure Drug Supply Chain Act of 2026
- Status: introduced
- Introduced: 2026-07-21
- Sponsor: Sen. Budd, Ted [R-NC] (R-NC)
- Cosponsors: 2
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-09-19

## Summary

**Stop imports of counterfeit and adulterated drugs from the People’s Republic of China and other countries of concern.** This bill would direct the Food and Drug Administration to block unlawful drug imports, expand inspections and enforcement, and boost visibility into active pharmaceutical ingredients and other key starting materials to reduce reliance on risky foreign sources.

## Cosponsors (2)

- Sen. Hassan, Margaret Wood [D-NH] (D-NH), 2026-09-17T00:00:00.000Z
- Sen. Tuberville, Tommy [R-AL] (R-AL), 2026-09-17T00:00:00.000Z

## Provisions PRIA read

- Deadlines for HHS drug guidance: benefit, low. If enacted, the bill would require the HHS Secretary to issue draft guidance defining "key starting material" within 90 days of enactment and final guidance within 180 days. It would also require proposed regulations within 90 days of enactment and final regulations within 180 days after the draft…
- Stronger import rules for drug firms: mixed, high. If enacted, the bill would direct the HHS Secretary to use FDA powers to block counterfeit, unapproved, misbranded, or adulterated drugs from entering the United States. The Secretary would be able to refuse entry, inspect or monitor compounding facilities, and work with the Attorney General on civ…
- Quarterly drug supply reporting rules: mixed, low. If enacted, the bill would change drug registrant reporting from annually to quarterly. Registrants would have to report detailed data for each active ingredient, key starting material, and any "acquired intermediate": identity, total amount used in the period (in units the Secretary specifies), an…

## Related bills

- 119-s-3923: Weather Research and Forecasting Innovation Reauthorization Act of 2026
- 119-s-1639: American Innovation and Jobs Act
- 119-s-1241: Sanctioning Russia Act of 2025
- 119-s-4429: Connected Vehicle Security Act of 2026
- 119-s-1816: Improving Seniors’ Timely Access to Care Act of 2025
- 119-s-1763: Motorsports Fairness and Permanency Act of 2025

## Sources
- [119-s-5043 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/5043)

## Related
- [119-s-3923: Weather Research and Forecasting Innovation Reauthorization Act of 2026](https://policyrisk.com/legislation/119-s-3923)
- [119-s-1639: American Innovation and Jobs Act](https://policyrisk.com/legislation/119-s-1639)
- [119-s-1241: Sanctioning Russia Act of 2025](https://policyrisk.com/legislation/119-s-1241)
- [119-s-4429: Connected Vehicle Security Act of 2026](https://policyrisk.com/legislation/119-s-4429)
- [119-s-1816: Improving Seniors’ Timely Access to Care Act of 2025](https://policyrisk.com/legislation/119-s-1816)
- [119-s-1763: Motorsports Fairness and Permanency Act of 2025](https://policyrisk.com/legislation/119-s-1763)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-5043 (as of 2026-09-19).